Scarica l'app Stockscreener
396.62
1.09%
-4.38
Dopo l'orario di chiusura:
396.62
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$401.00
Aprire:
$400.09
Volume 24 ore:
1.24M
Relative Volume:
0.76
Capitalizzazione di mercato:
$101.69B
Reddito:
$11.39B
Utile/perdita netta:
$3.64B
Rapporto P/E:
28.35
EPS:
13.99
Flusso di cassa netto:
$3.50B
1 W Prestazione:
+1.94%
1M Prestazione:
-14.18%
6M Prestazione:
-17.94%
1 anno Prestazione:
-16.62%
Intervallo 1D:
$393.05
$402.39
Intervallo di 1 settimana:
$388.00
$402.39
Portata 52W:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.43 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
722.01 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.26 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Enlaza Therapeutics Forms $2.4 Billion Collaboration with Vertex Pharmaceuticals - PharmExec
Transcript : Vertex Pharmaceuticals Incorporated Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 11 - MarketScreener
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report? - sg.finance.yahoo.com
Enlaza takes the helm in a $2B+ Vertex deal - BioWorld MedTech
Why Vertex Pharmaceuticals (VRTX) Is on Loomis Sayles Growth Fund’s Detractors List - AInvest
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - 富途牛牛
Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List - Yahoo Finance
Is Vertex Pharmaceuticals Incorporated meeting your algorithmic filter criteriaMarket Volume Summary & Entry and Exit Point Strategies - Newser
Vertex teams with Enlaza to expand gene therapy options - The Pharma Letter
Should you wait for a breakout in Vertex Pharmaceuticals IncorporatedPortfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Tools to assess Vertex Pharmaceuticals Incorporated’s risk profileGap Up & Weekly Market Pulse Updates - Newser
Sentiment analysis tools applied to Vertex Pharmaceuticals Incorporated2025 Market WrapUp & Safe Entry Zone Tips - Newser
Does Vertex Pharmaceuticals Incorporated meet Warren Buffett’s criteriaQuarterly Trade Review & Growth-Oriented Investment Plans - khodrobank.com
Is Vertex Pharmaceuticals Incorporated attractive for institutional investorsJuly 2025 Technicals & Weekly Breakout Stock Alerts - khodrobank.com
What does recent volatility data suggest for Vertex Pharmaceuticals IncorporatedJuly 2025 Catalysts & Smart Swing Trading Alerts - Newser
Stock Analysis | Vertex Pharmaceuticals OutlookMixed Technicals but Strong Fundamentals - AInvest
Vertex Stock Surges 2.55% on 44% Volume Spike to $740M Ranking 135th as $2B Collaboration with Enlaza Drives Strategic Expansion - AInvest
Vertex locks on to $2B covalent biologics deal with Enlaza - FirstWord Pharma
Relative strength of Vertex Pharmaceuticals Incorporated in sector analysis2025 Investor Takeaways & Weekly Consistent Profit Watchlists - Newser
Does Vertex Pharmaceuticals Incorporated outperform in volatile markets2025 Fundamental Recap & Safe Entry Zone Tips - khodrobank.com
Vertex Pharmaceuticals Partners with Enlaza Therapeutics in $45 Million Deal to Develop Autoimmune and Gene-Editing Therapies - geneonline.com
Vertex enlists Enlaza for gene therapy conditioning and autoimmune disease pact - Endpoints News
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact - BioSpace
Vertex Pharma, Enlaza sign R&D pact worth up to $2B plus equity - Seeking Alpha
Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods - Fierce Biotech
Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings - Yahoo Finance
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases | VR - GuruFocus
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases - Business Wire
Is Vertex Pharmaceuticals Incorporated still worth holding after the dipQuarterly Profit Review & Real-Time Buy Signal Alerts - Newser
Aug EndMonth: Does Vertex Pharmaceuticals Incorporated have declining or rising EPS2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - khodrobank.com
Is Vertex Pharmaceuticals Incorporated part of any major indexPortfolio Growth Summary & Community Verified Watchlist Alerts - khodrobank.com
Is Vertex Pharmaceuticals Incorporated currently under institutional pressureJuly 2025 Sector Moves & Free AI Powered Buy and Sell Recommendations - khodrobank.com
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Vertex Pharmaceuticals Incorporated stock retracement – recovery analysis2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
Using Bollinger Bands to evaluate Vertex Pharmaceuticals IncorporatedWeekly Stock Analysis & Free Fast Gain Swing Trade Alerts - Newser
Risk adjusted return profile for Vertex Pharmaceuticals Incorporated analyzedTrend Reversal & Free Reliable Trade Execution Plans - Newser
Vertex price shows more negative signsForecast today01-09-2025 - Economies.com
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - uk.finance.yahoo.com
Vertex Pharmaceuticals Incorporated stock trendline breakdownAnalyst Downgrade & Entry Point Confirmation Signals - Newser
Tools to monitor Vertex Pharmaceuticals Incorporated recovery probabilityTrade Analysis Summary & Capital Efficiency Focused Strategies - Newser
Price momentum metrics for Vertex Pharmaceuticals Incorporated explainedWeekly Trade Report & AI Forecasted Entry and Exit Points - Newser
Vertex Pharmaceuticals Incorporated Builds Base for Possible Rebound getLinesFromResByArray error: size == 0 - thegnnews.com
Visualizing Vertex Pharmaceuticals Incorporated stock with heatmapsJuly 2025 Sentiment & Free Reliable Trade Execution Plans - Newser
Will earnings trigger a reversal in Vertex Pharmaceuticals IncorporatedPortfolio Performance Summary & Technical Confirmation Trade Alerts - Newser
Is Vertex Pharmaceuticals Incorporated stock reversal real or fake2025 Risk Factors & Safe Capital Growth Trade Ideas - Newser
What high frequency data says about Vertex Pharmaceuticals IncorporatedRate Cut & Daily Risk Controlled Trade Plans - Newser
When is the best time to exit Vertex Pharmaceuticals IncorporatedTrade Exit Summary & Technical Confirmation Trade Alerts - Newser
How to build a custom watchlist for Vertex Pharmaceuticals IncorporatedBear Alert & Real-Time Stock Movement Alerts - Newser
Can Vertex Pharmaceuticals Incorporated recover in the next quarterWeekly Trading Summary & Verified Momentum Watchlists - Newser
Order flow analysis tools used on Vertex Pharmaceuticals Incorporated2025 Technical Overview & Daily Stock Trend Watchlist - Newser
Will breakout in Vertex Pharmaceuticals Incorporated lead to full recoveryEarnings Summary Report & Safe Capital Growth Stock Tips - Newser
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):